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Zonisamide (ZNS) is a sulphonamide antiepileptic drug (AED)
used to treat epilepsy around the world.1 Recent studies suggested
that ZNS is an effective treatment for motor and nonmotor
symptoms of Parkinson’s disease (PD) (for a review2). However,
only one randomized, double-blind, multicentre, placebo-con-
trolled study conducted in Japan3 demonstrated the efﬁcacy of ZNS
as add-on administration in treating motor symptoms in PD
patients, and most observations relating to the effectiveness of ZNS
for PD symptoms have been made in Japan, where the drug was
originally synthesized and released in March 2009 as an
antiparkinsonian agent.
Here we report the case of a Caucasian 78 year-old male patient
with longstanding PD and dementia, who came to our attention
because he developed nocturnal seizures; ZNS treatment signiﬁ-
cantly improved both his epilepsy and PD, without affecting
cognitive functions.
2. Methods
The patient was diagnosed with PD ten years before his
presentation with seizures. At ﬁrst, he had complained of resting
tremor of the right hand, but later he had gradually worsening
extrapyramidal symptoms with bradykinesia, dysarthria, hypo-
mimia, hyposmia and a camptocormic posture when walking. He
was initially treated with pramipexole, which was titrated up to a
dosage of 2.1 mg/day. After one year levodopa was added and
gradually increased to a dosage of 800 mg/day without fully
controlling his PD symptoms. Moreover, in the last four years prior* Corresponding author at: Neurologia, Universita` Campus Bio-Medico, Via
Alvaro del Portillo 200, Trigoria, 00128 Roma, Italy. Tel.: +39 06 225411286;
fax: +39 06 225411028.
E-mail address: m.tombini@unicampus.it (M. Tombini).
1059-1311/$ – see front matter  2013 British Epilepsy Association. Published by Else
http://dx.doi.org/10.1016/j.seizure.2013.01.011to presentation with seizures, he showed progressive cognitive
impairment with memory deﬁcits as well as moderate temporal
and spatial disorientation. For this reason he had been started on
rivastigmine 6 mg/day three years prior to the onset of his
seizures. The patient was referred with a history of two tonic–
clonic seizures, which had been observed by his wife. The second
of these seizures had happened two weeks after the ﬁrst. Both
episodes occurred from sleep, lasted 2 min and were followed by
confusion for about 10 min. There were no apparent precipitants
(i.e. fever, illness, alcohol or use of proconvulsant drugs). The
patient did not have a family or personal history of epilepsy or
seizures.
Neurological examination on admission to our department
showed a mild-to-moderate extrapyramidal syndrome. The motor
impairment had started signiﬁcantly to interfere with the patient’s
everyday life. He was increasingly dependent on family members
for dressing and bathing, had stopped cycling, and was unable to
pursue his hobbies. For these reasons he got depressed. The patient
did not experience ‘‘on’’ and/or ‘‘off’’ periods. The uniﬁed
Parkinson’s disease rating scale (UPDRS) Part III score (assessment
of motor function) – 1 h after administration of 200 mg levodopa –
was 36 (Table 1). In addition, there were signiﬁcant impairments in
UPDRS Part I (evaluation of mentation/cognition, behavior and
mood – score: 6) and Part II scores (self-evaluation of activities of
daily living – score 13, see Table 1). Neuropsychological evaluation
conﬁrmed slight cognitive impairment in several domains: mild
episodic memory deﬁcits and more severe difﬁculties with
attention, programming, logical reasoning and language. The
patient also showed slowing of cognitive processing speed. The
cognitive pattern was suggestive of a PD-related dementia.
The Mini Mental State Examination (MMSE) score was 22. Brain
MRI showed a mild chronic vascular leukoencephalopathy with
cortical atrophy. Finally, 24-h EEG monitoring revealed interictal
epileptiform abnormalities in the left frontotemporal regions
during NREM sleep. During wakefulness, the EEG showed a mild
slowing of background activity. After this evaluation ZNS was
added to the previously prescribed antiparkinsonian medication at
a dosage of 25 mg twice daily, and slowly titrated up to 100 mg
twice daily. At one-month follow-up the patient was seizure-free
without any adverse effects and demonstrated a clear improve-
ment of his extrapyramidal symptoms on neurological examina-
tion, especially in terms of tremor and bradykinesia (UPDRS Part
III = 24). The improvement was clinically signiﬁcant: the patient
regained his independence in everyday life and recovered his
interests, such as cycling and gardening; his mood also improvedvier Ltd. All rights reserved.
Table 1
Clinical scores.
Admission 1-Month follow up 6-Months follow up 1-Year follow up 6 Months and
1-year follow up
MMSE 22 23 24 25 25
UPDRS Part I 6 2 3 3 3
UPDRS Part II 13 9 9 9 9
UPDRS Part III 36 24 25 25 26
The Mini Mental State Examination (MMSE) and the uniﬁed Parkinson’s disease rating scale (UPDRS) were performed in the morning 1 h after administration of 200 mg
levodopa.
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was maintained at six months and one-year follow-up (Table 1)
without any changes of his anti-PD drugs. The patient’s cognitive
status also remained stable (Table 1).
3. Discussion
This observation offers support for the efﬁcacy of ZNS – a well-
known antiepileptic drug - as a treatment for motor and nonmotor
symptoms of PD in a Caucasian man, as already described by
Japanese authors.2–4Moreover, we describe the ﬁrst use of ZNS in a
patient with PD dementia. As previously suggested,3–7 the main
improvements were noted in terms of tremor and bradykinesia.
However, these improvements had a signiﬁcant effect on our
patient’s general behavior, mood and self-sufﬁciency in perform-
ing activities of daily living.
The pharmacological mechanisms explaining ZNS’s beneﬁcial
effects in PD are unclear, and both dopaminergic and nondopa-
minergic mechanisms seem to be involved. In particular, data
coming from animal studies demonstrates that ZNS has a biphasic
effect on the dopaminergic system: therapeutic doses of the drug
increase intracellular and extracellular dopamine in the rat
striatum, while supratherapeutic doses reduce intracellular dopa-
mine.8 Moreover, ZNS blocks T-type calcium channels and inhibits
MAO-B,2 but these effects do not seem to be the main mode of
action. In our case low doses of ZNS led to seizure control as well as
an improvement of PD symptoms. The improvement of parkinso-
nian symptoms was maintained after six months and one-year
follow-up, whilst cognition remained stable. It is conceivable that
the latter observation was related to the neuroprotective proper-
ties of ZNS, clearly documented in several experimental studies in
animals.9–10 Having said that, it is possible that the arrest of
cognitive decline was due to the improvement of the patient’s
mood: ZNS has a serotonergic effect that seems to be associated
with improvements in bipolar depression.11
It is possible that the involvement of the cerebral cortex in the
patient’s neurodegenerative process explained the occurrence of
seizures in our case, as leukoencephalopathy was mild and mostly
affected subcortical regions. In fact, there was no clear correlation
between the interictal EEG focus localized in the left mesiotem-
poral regions and the ischemic lesions detected on brain MRI. PD
has consistently been found to be associated eventually with
cortical damage, beginning in the anteromedial temporal meso-
cortex.12
ZNS treatment was well tolerated in our patient without
affecting cognitive functions or triggering behavioral or psycho-
logical symptoms. While PD occurs about three times more often in
patients with epilepsy,13 surprisingly there are no studies on the
efﬁcacy and tolerability of AEDs in these patients. Indeed different
AEDs, such as carbamazepine, phenytoin and tiagabine, have been
associated with movement disorders, mainly dystonic reactions14or athetosis15; in particular, valproate is widely known to induce
tremor.14 In keeping with our observation, a low dose of ZNS has
recently been used with beneﬁt and without adverse effects to
treat parkinsonism in a few cases of dementia with Lewy bodies,
associated with psychotic and behavioral symptoms.16,17
In conclusion, we propose that low dose ZNS could be an
optimal and well-tolerated choice for the treatment of seizures in
patients affected by PD, even when dementia coexists; other AEDs,
in particular valproate, should be avoided in these patients as it
may worsen their extrapyramidal symptoms.
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